Christopher R. Smith

Author

Mount Sinai Hospital ORCID

Also Known As

C R SMITH, C R Smith, C Smith, C. R. Smith, C. SMITH, C. Smith, C.R. SMITH, C.R. Smith, C.R.R. Smith, Chris R Smith

182

Publications

4.2K

Citations

H-Index

118

Concepts

All Affiliations

Mount Sinai Hospital University of Toronto Mirati Therapeutics (United States)University Health Network Cardiff University

About

Christopher R. Smith is an author at Mount Sinai Hospital specializing in medicine, pharmacology, and drug discovery.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	19	25	1.7K
2	Natural Sciences	7	7	494
3	Health Sciences	4	4	62
4	Engineering	2	2	91
5	Public Health	2	2	123

Christopher R. Smith

Publications

Citations

H-Index

Page 1

	Year	Citations
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS <sup>G12D</sup> Inhibitor Xiaolun Wang, Shelley Allen, James F. Blake, Journal of Medicinal Chemistry	2021	644
Anti-tumor efficacy of a potent and selective non-covalent KRASG12D inhibitor Jill Hallin, Vickie Bowcut, Andrew Calinisan, Nature Medicine MedicinePharmacologyPharmacotherapyAnti-tumor EfficacyAnti-cancer Agent	2022	465
Integrating de novo and inherited variants in 42,607 autism cases identifies mutations in new moderate-risk genes Xueya Zhou, Pamela Feliciano, Chang Shu, Nature Genetics	2022	423
Mining biomarkers in human sera using proteomic tools Rulin Zhang, Lisa Barker, Deborah Pinchev, PROTEOMICS Low Abundance ProteinsProtein PurificationProteomic TechnologyBiomarker (Medicine)Alzheimer's Disease	2004	186
Sigma 2 receptors as potential biomarkers of proliferation in breast cancer. Robert H. Mach, Christopher R. Smith, Isaf Al‐Nabulsi, PubMed Tumor BiologySigma ReceptorsBreast OncologyEndocrine-related CancerSigma 2	1997	177
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with <i>MTAP</i> -Deleted Cancer Lars D. Engstrom, Ruth Aranda, Laura Waters, Cancer Discovery	2023	163
Identification of Five Candidate Lung Cancer Biomarkers by Proteomics Analysis of Conditioned Media of Four Lung Cancer Cell Lines Chris Planque, Vathany Kulasingam, Christopher R. Smith, Molecular & Cellular Proteomics	2009	144
Mining the Ovarian Cancer Ascites Proteome for Potential Ovarian Cancer Biomarkers Cynthia Kuk, Vathany Kulasingam, C. Geeth Gunawardana, Molecular & Cellular Proteomics	2008	142
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of <i>MTAP</i> -Deleted Cancers Christopher R. Smith, Ruth Aranda, Thomas P. Bobinski, Journal of Medicinal Chemistry	2022	139
SGX523 is an exquisitely selective, ATP-competitive inhibitor of the MET receptor tyrosine kinase with antitumor activity <i>in vivo</i> Sean G. Buchanan, J. Hendle, Patrick S. Lee, Molecular Cancer Therapeutics Gene AmplificationAntitumor ActivityChemoprevention StrategyExquisite SelectivityCancer Biology	2009	130

Page 1